PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
PTC THERAPEUTICS, INC. (PTCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results – Robust Q2 performance with total revenue of $361 million, including $239 million of product revenue – – Full-year 2026 expected total revenue increased to $1.18 to $1
How this was made
The 30-second read
Why it matters
The most tradable elements are the raised full-year product revenue guidance, the reported Q2 revenue mix (Sephience growth), and the INVEST-HD milestone tied to Novartis funding. Pipeline trial initiations and board appointment add longer-dated optionality but are secondary to the near-term financial outlook.
Market read
Raised 2026 product revenue guidance and strong Q2 product revenue growth are likely the primary drivers for PTCT trading, with clinical pipeline updates providing additional upside optionality.
What to watch
Convertible note issuance and repurchase details can affect dilution/financing optics, and FDA engagement timing for PIVOT-HD 24-month results may shift expectations.
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Second-quarter total revenues increased to $ 360,519 from $ 178,875, net income was $ 83,496 versus a net loss of $ (64,849), Sephience net product revenues were $151.3 million, and the company raised full-year product revenue guidance to $850 to $950 million.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenuesGAAP | $360.5M | – | – |
| Net product revenueGAAP | $238.8M | – | over 100% increase |
| Collaboration and license revenueGAAP | $ 50,595 | – | – |
| Royalty revenueGAAP | $71.11M | – | – |
| Total net product revenue and royalty revenueGAAP | $309.9M | – | – |
| Cost of product, collaboration and license sales, excluding amortization of acquired intangible assetsGAAP | 19,921 | – | – |
| Amortization of acquired intangible assetsGAAP | 11,841 | – | – |
| Research and developmentGAAP | $99.15M | – | – |
| Research and developmentnon-GAAP | $88.60M | – | – |
| Share-based compensation expense in research and developmentother | 10,547 | – | – |
| Selling, general and administrativeGAAP | $80.63M | – | – |
| Selling, general and administrativenon-GAAP | $67.89M | – | – |
| Share-based compensation expense in selling, general and administrativeother | 12,744 | – | – |
| Total operating expensesGAAP | 211,542 | – | – |
| Income (loss) from operationsGAAP | 148,977 | – | – |
| Interest expense, netGAAP | (48,481) | – | – |
| Other expense, netGAAP | (2,951) | – | – |
| Income (loss) before income tax (expense) benefitGAAP | 97,545 | – | – |
| Income tax (expense) benefitGAAP | (14,049) | – | – |
| Net income (loss) attributable to common stockholdersGAAP | $83.50M | – | – |
| Net income (loss) per share, basicGAAP | $ 1.01 | – | – |
| Net income (loss) per share, dilutedGAAP | $ 0.92 | – | – |
| Weighted-average shares outstanding, basicGAAP | 83,006,808 | – | – |
| Weighted-average shares outstanding, dilutedGAAP | 92,020,009 | – | – |
| Six-month total revenuesGAAP | 633,070 | – | – |
| Six-month net income (loss) attributable to common stockholdersGAAP | $ 80,687 | – | – |
| Six-month net income (loss) per share, basicGAAP | $ 0.97 | – | – |
| Six-month net income (loss) per share, dilutedGAAP | $ 0.90 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| SephienceContinued broad uptake and geographical expansion, with the majority of revenue from the US and increasing contributions internationally. | $151.3M | 21% growth compared to the first quarter of 2026 | – |
| Translarna | $42.2M | – | – |
| EmflazaContinued generic erosion. | $24.6M | – | – |
| Evrysdi royalty revenueRoche reported Evrysdi year-to-date sales of approximately 968 CHF million. | $71.1M | – | – |
Full-year 2026 outlook
- Revenue$1.18 to $1.28 billion
- Operating expenses$775 to $815 million
- NoteTotal product revenue: $850 to $950 million
- NoteNon-GAAP R&D and SG&A expense: $680 to $720 million
- NoteEstimated non-cash, stock-based compensation expense: $95 million
Capital returns
- In June 2026, PTC issued $550.0 million of senior convertible notes due in 2031 at 0% coupon.
- Concurrent with the transaction, PTC repurchased the majority of its 1.5% senior convertible notes due in September 2026.
What drove it
- Sephience net product revenues were $151.3 million, with 1,647 patients on commercial therapy worldwide as of June 30, 2026.
- PTC recorded a $50.0 million development milestone from Novartis for the first patient dosed in the ongoing INVEST-HD Phase 3 study, recorded as collaboration revenue.
- Royalty revenue was supported by Roche-reported Evrysdi year-to-date sales of approximately 968 CHF million.
- GAAP R&D expenses were $99.2 million compared to $113.0 million, and GAAP SG&A expenses were $80.6 million compared to $85.3 million.
Concerns
- Translarna net product revenues were $42.2 million compared to $59.5 million for the second quarter of 2025.
- Emflaza net product revenues were $24.6 million compared to $36.4 million for the second quarter of 2025, due to continued generic erosion.
- Interest expense, net was (48,481), compared to (30,358) for the second quarter of 2025.
- Total debt was $ 590,970 at June 30, 2026, compared to $ 286,631 at December 31, 2025.
- Total stockholders' deficit was $ (165,363) at June 30, 2026.
What to watch
- Plan to engage with FDA in 2H 2026 to discuss finalized PIVOT-HD 24-month results.
- INVEST-HD is targeting enrollment of approximately 770 individuals with early symptomatic disease.
- The vatiquinone PROVE-FA study to support NDA resubmission is expected to initiate in Q3 2026.
- The Phase 2a study of PTC844 is expected to initiate in Q3 2026.
- PTC303 is planned to enter the clinic in 2027.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities: $ 2,229,082 at June 30, 2026, compared to $ 1,945,371 at December 31, 2025.
- Total assets: $ 3,250,477 at June 30, 2026, compared to $ 2,898,767 at December 31, 2025.
- Total debt: $ 590,970 at June 30, 2026, compared to $ 286,631 at December 31, 2025.
- Total liability for sale of future royalties: $ 2,321,434 at June 30, 2026, compared to $ 2,308,366 at December 31, 2025.
- Total liabilities: $ 3,415,840 at June 30, 2026, compared to $ 3,104,080 at December 31, 2025.
- Total stockholders' deficit: $ (165,363) at June 30, 2026, compared to $ (205,313) at December 31, 2025.
- Shares issued and outstanding: 83,327,286 at June 30, 2026, compared to 81,474,366 at December 31, 2025.
Analysis
PTC reported second-quarter total revenues of $ 360,519, compared with $ 178,875 in the second quarter of 2025. Net product revenue was $ 238,819, compared with $ 118,329, while collaboration and license revenue was $ 50,595, including the $50.0 million Novartis development milestone recorded for the first patient dosed in INVEST-HD. Royalty revenue was $ 71,105, compared with $ 57,605, supported by Roche-reported Evrysdi year-to-date sales of approximately 968 CHF million.
Sephience was the principal commercial growth driver. Sephience net product revenues were $151.3 million and increased 21% compared with the first quarter of 2026, with 1,647 patients on commercial therapy worldwide as of June 30, 2026. The company cited continued broad uptake and geographical expansion, with most revenue from the US and increasing international contributions. This growth offset lower revenue from Translarna, at $42.2 million versus $59.5 million, and Emflaza, at $24.6 million versus $36.4 million amid continued generic erosion.
The revenue increase and lower operating costs moved the company to profitability. Income from operations was 148,977, compared with a loss from operations of (34,957), and net income attributable to common stockholders was $ 83,496 versus a loss of $ (64,849). GAAP R&D was $ 99,150 versus $ 112,990 and GAAP SG&A was $ 80,630 versus $ 85,262. Interest expense, net was (48,481), compared with (30,358), and total debt was $ 590,970 at June 30, 2026.
Liquidity was $ 2,229,082 of cash, cash equivalents and marketable securities at June 30, 2026. During June, PTC issued $550.0 million of 0% senior convertible notes due in 2031 and repurchased the majority of its 1.5% senior convertible notes due in September 2026. Full-year 2026 total revenue guidance was increased to $1.18 to $1.28 billion, product revenue guidance was raised to $850 to $950 million, and GAAP R&D and SG&A expense guidance remained $775 to $815 million.
Pipeline execution remains a key operating focus. PTC reported positive PIVOT-HD long-term extension results, ongoing enrollment in Novartis-funded INVEST-HD, an expected Q3 2026 initiation for the vatiquinone PROVE-FA study, initiation of the PTC612 Phase 1 study in Q2 2026, and an expected Q3 2026 initiation for the PTC844 Phase 2a study. The company also named PTC303 as its MSH3 splicing program development candidate, with a plan to enter the clinic in 2027.
Management, verbatim
Our teams delivered another strong quarter enabling us to again raise 2026 product revenue guidance,
Matthew B. Klein, M.D., Chief Executive Officer
We also made a number of advances in our R&D pipeline, including identification of our next small molecule splicing development candidate, PTC303, targeting somatic expansion disorders including Huntington’s disease and myotonic dystrophy. In addition, we initiated the Phase 1 study of PTC612, our differentiated NLRP3 small molecule.
Matthew B. Klein, M.D., Chief Executive Officer
Not in the filing
stated, not guessed- Gross profit and gross margin
- Operating cash flow
- Free cash flow
- Cash flow statement
- Non-GAAP net income
- Non-GAAP earnings per share
- Non-GAAP operating income
- Quarter-over-quarter total revenue comparison
- Prior-quarter revenue figures for Translarna, Emflaza, royalty revenue, collaboration and license revenue, and total revenue
- Year-over-year percentage changes for individual product revenues and royalty revenue
- Dividend information
- Common-share repurchases
- Forward gross-margin guidance
- Forward tax-rate guidance
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
PTC Therapeutics filed an 8-K with Q2 2026 results, corporate updates, and updated full-year 2026 financial guidance, plus pipeline and collaboration milestones.
Ticker impact
PTC raised full-year 2026 product revenue guidance to $850 to $950 million and reported Q2 revenue of $361 million, including $239 million product revenue.
Likely positive bias for PTCT into the next few sessions as traders digest raised revenue guidance and Sephience momentum.
The filing discloses fresh, decision-relevant numbers: Q2 results, raised 2026 revenue/product revenue guidance, and a $50 million Novartis milestone tied to INVEST-HD first patient dosed.
Market effects
Biopharma investors may rotate toward profitable commercial franchises and validated rare-disease uptake, given Sephience launch momentum and royalty visibility.
Limited direct regional spillover; primarily US-listed biotech sentiment.
Global rare-disease treatment demand signals may influence peers with similar commercial launch dynamics and royalty streams.
Counterpoint
Despite the guidance raise, Translarna revenue declined and Emflaza faced continued generic erosion, which could cap upside if Sephience growth slows.
Key entities
- issuerPTC Therapeutics, Inc.
Reported Q2 2026 financial results, raised 2026 product revenue guidance, and updated pipeline and collaboration milestones.
- partnerNovartis
Funded INVEST-HD Phase 3 and triggered a $50 million milestone payment upon first patient dosed.
- regulatorFDA
PTC plans to engage in 2H 2026 regarding PIVOT-HD 24-month results being finalized.
